TY - JOUR
T1 - Pharmacologic biomarkers in the development of stratified cancer medicine
AU - Figg, William Douglas
AU - Newell, David R.
PY - 2014/5/15
Y1 - 2014/5/15
N2 - Clinical pharmacologic research plays a vital role in cancer drug development. In recent years, biomarker studies have become integral to this process, specifically the use of pharmacologic biomarkers in the development of targeted therapies and their translation to clinical practice. In this overview, we discuss the validation of pharmacodynamics (PD) biomarkers and highlight the circulating tumor DNA as a promising cancer biomarker to illustrate howPDbiomarkers can be powerful tools for guiding treatment strategies.We provide insights into PD biomarker approaches for future development of novel therapies and their role in cancer medicine.
AB - Clinical pharmacologic research plays a vital role in cancer drug development. In recent years, biomarker studies have become integral to this process, specifically the use of pharmacologic biomarkers in the development of targeted therapies and their translation to clinical practice. In this overview, we discuss the validation of pharmacodynamics (PD) biomarkers and highlight the circulating tumor DNA as a promising cancer biomarker to illustrate howPDbiomarkers can be powerful tools for guiding treatment strategies.We provide insights into PD biomarker approaches for future development of novel therapies and their role in cancer medicine.
UR - http://www.scopus.com/inward/record.url?scp=84901008744&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-14-0511
DO - 10.1158/1078-0432.CCR-14-0511
M3 - Article
C2 - 24831275
AN - SCOPUS:84901008744
SN - 1078-0432
VL - 20
SP - 2525
EP - 2529
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 10
ER -